Loading market dashboard
KALA BIO, Inc.
KALAHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 50 pre-split shares.
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Valuation and Earnings This table compares Celularity and
Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations
The company confirmed that BIRA is now live in client-controlled environments, marking its entry into revenue-generating AI infrastructure.
KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company.
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio's with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”).
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry Toronto, Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's Researgency.ai agentic artificial intelligence platform to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. ("Filament"). The engagement will deploy Kala Bio's purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.
Open-source breakthrough demonstrates AI agents can run 100+ experiments overnight-reinforcing the agentic R&D paradigm Researgency.ai is bringing to life sciences with Kala Bio (KALA) Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Younet.ai, a Toronto-based AI technology company specializing in enterprise-grade private LLM solutions, today announced that the recent release of AutoResearch by AI pioneer Andrej Karpathy provides strong external validation for the autonomous research-agent approach underpinning Researgency.ai, Younet's agentic research platform being developed in collaboration with Kala Bio, Inc. (NASDAQ: KALA). AutoResearch is an open-source tool that enables AI agents to autonomously conduct 100+ machine-learning experiments overnight on a single GPU, demonstrating a step-change in research velocity via continuous agentic iteration.
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks
Younet AI Partners with KALA BIO to Deploy AI Infrastructure for the Biotech Industry Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Stock Trend Capital Inc. (CSE: STCQ) (FSE: P0G) (OTC Pink: STOCF) (the "Company" or "Stock Trend") is pleased to provide shareholders with an update regarding its investment in Younet AI ("Younet"), a privately held Canadian company developing artificial-intelligence platforms and tools enabling users to build customized AI models trained on their own data to automate tasks, enhance productivity, and improve workflows and communications. On March 4, 2026, a strategic partnership between Younet AI and KALA BIO Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company, was announced.
